List view / Grid view
4 November 2013 | By Johnson & Johnson
The resolution includes total settlement amounts of approximately $2 billion to the federal government...
2 November 2013 | By Creston Health
“The VALENCE results demonstrate the high efficacy of a 24-week, sofosbuvir-based, interferon-free treatment regimen for genotype 3 HCV patients..."
2 November 2013 | By Boehringer Ingelheim
"These data are encouraging and reinforce the potential benefits of faldaprevir* as an effective treatment..."
2 November 2013 | By Portland Communications
"Mundipharma recognises the current economic environment and resulting budget constraints for healthcare systems..."
2 November 2013 | By Janssen R&D Ireland
“The breadth of simeprevir data presented at AASLD reinforce its potential as a treatment option..."
2 November 2013 | By Merck
Sustained virologic response at post-treatment follow-up week 12 (SVR 12) seen in 100 percent of patients to date in two of the three combination arms studied...
2 November 2013 | By Bristol-Myers Squibb Company
"We are pleased to be one step closer to bringing a potential new treatment option to the many people living with HCV..."
1 November 2013 | By Janssen
Janssen continues to undertake clinical studies with telaprevir to identify opportunities to serve specialized and hard-to-treat patients...
1 November 2013 | By Novo Nordisk
FlexTouch® is the latest innovation in prefilled insulin delivery systems from Novo Nordisk...
31 October 2013 | By Novo Nordisk
Sales growth of 8% driven by Victoza®, Levemir® og NovoRapid®...
"Following a thorough and extensive search it became clear that Marc possessed the rare blend of financial, business and science experience..."
30 October 2013 | By Johnson & Johnson
“The EMA Marketing Authorisation Application is an important milestone in the development of ibrutinib...”
30 October 2013 | By Teva Pharmaceutical Industries Ltd
Dr. Jeremy Levin will step down as President and Chief Executive Officer...
30 October 2013 | By Abbott
The MitraClip device provides physicians with a breakthrough treatment option for patients suffering from MR...
30 October 2013 | By AstraZeneca
The goal of CALIMA is to determine whether benralizumab reduces the number of exacerbations in patients with severe asthma that remains uncontrolled...
